BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos SA. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. J Crohns Colitis 2021:jjab212. [PMID: 34972203 DOI: 10.1093/ecco-jcc/jjab212] [Reference Citation Analysis]
2 Yde CC, Jensen HM, Christensen N, Servant F, Lelouvier B, Lahtinen S, Stenman LK, Airaksinen K, Kailanto HM. Polydextrose with and without Bifidobacterium animalis ssp. lactis 420 drives the prevalence of Akkermansia and improves liver health in a multi-compartmental obesogenic mice study. PLoS One 2021;16:e0260765. [PMID: 34855861 DOI: 10.1371/journal.pone.0260765] [Reference Citation Analysis]
3 Qian J, Chen X, Shu S, Zhang W, Fang B, Chen X, Zhao Y, Liu Z, Liang G. Design and synthesis novel di-carbonyl analogs of curcumin (DACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI). European Journal of Medicinal Chemistry 2019;167:414-25. [DOI: 10.1016/j.ejmech.2019.02.042] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
4 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920 [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
5 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases 2019;7:E27. [PMID: 30823570 DOI: 10.3390/diseases7010027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
6 Li K, Zhang L, Xue J, Yang X, Dong X, Sha L, Lei H, Zhang X, Zhu L, Wang Z, Li X, Wang H, Liu P, Dong Y, He L. Dietary inulin alleviates diverse stages of type 2 diabetes mellitus via anti-inflammation and modulating gut microbiota in db/db mice. Food Funct 2019;10:1915-27. [PMID: 30869673 DOI: 10.1039/c8fo02265h] [Cited by in Crossref: 53] [Cited by in F6Publishing: 31] [Article Influence: 17.7] [Reference Citation Analysis]
7 Hupa-Breier KL, Dywicki J, Hartleben B, Wellhöner F, Heidrich B, Taubert R, Mederacke YE, Lieber M, Iordanidis K, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E. Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. Biomedicines 2021;9:353. [PMID: 33808404 DOI: 10.3390/biomedicines9040353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ye J, Lin Y, Wang Q, Li Y, Zhao Y, Chen L, Wu Q, Xu C, Zhou C, Sun Y, Ye W, Bai F, Zhou T. Integrated Multichip Analysis Identifies Potential Key Genes in the Pathogenesis of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2020;11:601745. [PMID: 33324350 DOI: 10.3389/fendo.2020.601745] [Reference Citation Analysis]
9 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Reference Citation Analysis]
10 Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Reference Citation Analysis]
11 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Kuang L, Zhou W, Jiang Y. Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis. PLoS One 2021;16:e0260479. [PMID: 34855819 DOI: 10.1371/journal.pone.0260479] [Reference Citation Analysis]
13 Liu HJ, Cao ST, Wen BY, Han X, Li Y, Li S, Li J, Zhang L. Rotundic acid ameliorates non-alcoholic steatohepatitis via SREBP-1c/ SCD1 signaling pathway and modulating gut microbiota. Int Immunopharmacol 2021;99:108065. [PMID: 34426119 DOI: 10.1016/j.intimp.2021.108065] [Reference Citation Analysis]
14 Fontes A, Alemany-Pagès M, Oliveira PJ, Ramalho-Santos J, Zischka H, Azul AM. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. Int J Mol Sci 2019;20:E3987. [PMID: 31426291 DOI: 10.3390/ijms20163987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
15 Augustyn M, Grys I, Kukla M. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clin Exp Hepatol. 2019;5:1-10. [PMID: 30915401 DOI: 10.5114/ceh.2019.83151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
16 Saeedi BJ, Liu KH, Owens JA, Hunter-Chang S, Camacho MC, Eboka RU, Chandrasekharan B, Baker NF, Darby TM, Robinson BS, Jones RM, Jones DP, Neish AS. Gut-Resident Lactobacilli Activate Hepatic Nrf2 and Protect Against Oxidative Liver Injury. Cell Metab 2020;31:956-968.e5. [PMID: 32213347 DOI: 10.1016/j.cmet.2020.03.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
17 Cremonini E, Daveri E, Mastaloudis A, Adamo AM, Mills D, Kalanetra K, Hester SN, Wood SM, Fraga CG, Oteiza PI. Anthocyanins protect the gastrointestinal tract from high fat diet-induced alterations in redox signaling, barrier integrity and dysbiosis. Redox Biol 2019;26:101269. [PMID: 31330482 DOI: 10.1016/j.redox.2019.101269] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
18 Baratta F, Pastori D, Bartimoccia S, Cammisotto V, Cocomello N, Colantoni A, Nocella C, Carnevale R, Ferro D, Angelico F, Violi F, Del Ben M. Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E1732. [PMID: 32531941 DOI: 10.3390/nu12061732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
19 Abenavoli L, Scarpellini E, Colica C, Boccuto L, Salehi B, Sharifi-Rad J, Aiello V, Romano B, De Lorenzo A, Izzo AA, Capasso R. Gut Microbiota and Obesity: A Role for Probiotics. Nutrients. 2019;11:2690. [PMID: 31703257 DOI: 10.3390/nu11112690] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 25.0] [Reference Citation Analysis]
20 Xiong F, Zheng Z, Xiao L, Su C, Chen J, Gu X, Tang J, Zhao Y, Luo H, Zha L. Soyasaponin A2 Alleviates Steatohepatitis Possibly through Regulating Bile Acids and Gut Microbiota in the Methionine and Choline-Deficient (MCD) Diet-induced Nonalcoholic Steatohepatitis (NASH) Mice. Mol Nutr Food Res 2021;65:e2100067. [PMID: 34047448 DOI: 10.1002/mnfr.202100067] [Reference Citation Analysis]
21 Bomhof MR, Parnell JA, Ramay HR, Crotty P, Rioux KP, Probert CS, Jayakumar S, Raman M, Reimer RA. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr 2019;58:1735-45. [PMID: 29779170 DOI: 10.1007/s00394-018-1721-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
22 Lee YC, Wang JL, Dong YH, Chen HC, Wu LC, Chang CH. Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study. PLoS Med 2019;16:e1002894. [PMID: 31518344 DOI: 10.1371/journal.pmed.1002894] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Okuno T, Kakehashi A, Ishii N, Fujioka M, Gi M, Wanibuchi H. mTOR Activation in Liver Tumors Is Associated with Metabolic Syndrome and Non-Alcoholic Steatohepatitis in Both Mouse Models and Humans. Cancers (Basel) 2018;10:E465. [PMID: 30469530 DOI: 10.3390/cancers10120465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
24 Spivak H, Munz Y, Rubin M, Raz I, Shohat T, Blumenfeld O. Omega-loop gastric bypass is more effective for weight loss but negatively impacts liver enzymes: a registry-based comprehensive first-year analysis. Surgery for Obesity and Related Diseases 2018;14:175-80. [DOI: 10.1016/j.soard.2017.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
25 Atif M, Warner S, Oo YH. Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells. Hepatol Int 2018;12:305-14. [PMID: 30027532 DOI: 10.1007/s12072-018-9882-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
26 Kuraji R, Sekino S, Kapila Y, Numabe Y. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. Periodontol 2000 2021;87:204-40. [PMID: 34463983 DOI: 10.1111/prd.12387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yuan X, Pan Z, Jin C, Ni Y, Fu Z, Jin Y. Gut microbiota: An underestimated and unintended recipient for pesticide-induced toxicity. Chemosphere 2019;227:425-34. [PMID: 31003127 DOI: 10.1016/j.chemosphere.2019.04.088] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 18.7] [Reference Citation Analysis]
28 Elvira-Torales LI, Periago MJ, González-Barrio R, Hidalgo N, Navarro-González I, Gómez-Gallego C, Masuero D, Soini E, Vrhovsek U, García-Alonso FJ. Spinach consumption ameliorates the gut microbiota and dislipaemia in rats with diet-induced non-alcoholic fatty liver disease (NAFLD). Food Funct 2019;10:2148-60. [PMID: 30938723 DOI: 10.1039/c8fo01630e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
29 Ruuskanen MO, Åberg F, Männistö V, Havulinna AS, Méric G, Liu Y, Loomba R, Vázquez-Baeza Y, Tripathi A, Valsta LM, Inouye M, Jousilahti P, Salomaa V, Jain M, Knight R, Lahti L, Niiranen TJ. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes 2021;13:1-22. [PMID: 33651661 DOI: 10.1080/19490976.2021.1888673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
30 Singh A, Garg R, Lan N, Siddiqui MT, Gupta M, Alkhouri N. Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:591-8. [DOI: 10.1007/s12664-020-01087-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Pastori D, Ettorre E, Carnevale R, Nocella C, Bartimoccia S, Del Sordo E, Cammisotto V, Violi F, Pignatelli P, Saliola M, Casciaro MA, Farcomeni A, Rubino L, Marchese C, Santulli M, Vasaturo F, Castellani V, Menichelli D. Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. Atherosclerosis 2019;289:195-200. [DOI: 10.1016/j.atherosclerosis.2019.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
32 Liu B, Deng X, Jiang Q, Li G, Zhang J, Zhang N, Xin S, Xu K. Scoparone alleviates inflammation, apoptosis and fibrosis of non-alcoholic steatohepatitis by suppressing the TLR4/NF-κB signaling pathway in mice. International Immunopharmacology 2019;75:105797. [DOI: 10.1016/j.intimp.2019.105797] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
33 Song BJ, Abdelmegeed MA, Cho YE, Akbar M, Rhim JS, Song MK, Hardwick JP. Contributing Roles of CYP2E1 and Other Cytochrome P450 Isoforms in Alcohol-Related Tissue Injury and Carcinogenesis. Adv Exp Med Biol 2019;1164:73-87. [PMID: 31576541 DOI: 10.1007/978-3-030-22254-3_6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
34 Philips CA, Augustine P, Yerol PK, Ramesh GN, Ahamed R, Rajesh S, George T, Kumbar S. Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease. J Clin Transl Hepatol. 2020;8:87-99. [PMID: 32274349 DOI: 10.14218/jcth.2019.00035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
35 Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci 2021;22:4156. [PMID: 33923817 DOI: 10.3390/ijms22084156] [Reference Citation Analysis]
36 Birková A, Hubková B, Čižmárová B, Bolerázska B. Current View on the Mechanisms of Alcohol-Mediated Toxicity. Int J Mol Sci 2021;22:9686. [PMID: 34575850 DOI: 10.3390/ijms22189686] [Reference Citation Analysis]
37 de Oliveira DG, de Faria Ghetti F, Moreira APB, Hermsdorff HHM, de Oliveira JM, de Castro Ferreira LEVV. Association between dietary total antioxidant capacity and hepatocellular ballooning in nonalcoholic steatohepatitis: a cross-sectional study.Eur J Nutr. 2019;58:2263-2270. [PMID: 30019089 DOI: 10.1007/s00394-018-1776-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
38 Konturek PC, Harsch IA, Konturek K, Schink M, Konturek T, Neurath MF, Zopf Y. Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver? Med Sci (Basel) 2018;6:E79. [PMID: 30227645 DOI: 10.3390/medsci6030079] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
39 Zhao W, Xiao M, Yang J, Zhang L, Ba Y, Xu R, Liu Z, Zou H, Yu P, Wu X, Chen X. The combination of Ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease. Phytomedicine 2019;63:153039. [DOI: 10.1016/j.phymed.2019.153039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
40 Zhou HH, Wang G, Luo L, Ding W, Xu JY, Yu Z, Qin LQ, Wan Z. Dietary lactoferrin has differential effects on gut microbiota in young versus middle-aged APPswe/PS1dE9 transgenic mice but no effects on cognitive function. Food Nutr Res 2021;65. [PMID: 34776831 DOI: 10.29219/fnr.v65.5496] [Reference Citation Analysis]
41 Jiang Y, Wan Y, Li J, Zhao Y, Ma Y, Yu J, Yuan D, Xiang S, Du F, Wu X, Li M, Chen Y, Xiao Z, Wen Q, Hu W, Shen J. Alterations in Intestinal Microbiota Composition in Mice Treated With Vitamin D3 or Cathelicidin. Front Oncol 2021;11:700038. [PMID: 35004267 DOI: 10.3389/fonc.2021.700038] [Reference Citation Analysis]
42 Wu X, Li J, Zhou Z, Lin Z, Pang S, Bhatt P, Mishra S, Chen S. Environmental Occurrence, Toxicity Concerns, and Degradation of Diazinon Using a Microbial System. Front Microbiol 2021;12:717286. [PMID: 34790174 DOI: 10.3389/fmicb.2021.717286] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Huang J, Li W, Liao W, Hao Q, Tang D, Wang D, Wang Y, Ge G. Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet. Food Funct 2020;11:9924-35. [PMID: 33095225 DOI: 10.1039/d0fo02152k] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
44 Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab 2021;50:101143. [PMID: 33346069 DOI: 10.1016/j.molmet.2020.101143] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]